ライフサイエンスコーパス: Bruton's tyrosine kinase

1 ectors phospholipase C (PLC)gamma2, Akt, and Bruton's tyrosine kinase.

2 on factor and a target of phosphorylation by Bruton's tyrosine kinase.

3 ction of TEC family tyrosine kinases such as Bruton's tyrosine kinase.

4 r II-I), which encodes BAP-135, a target for Bruton's tyrosine kinase.

5 her revealed that DOK3 was phosphorylated by Bruton's tyrosine kinase.

6 These results are extended into Btk (Bruton's tyrosine kinase), a Tec family kinase linked to

7 mast cell proliferation was not dependent on Bruton's tyrosine kinase, a downstream effector of PI3K,

8 Moreover, we observed that Bruton's tyrosine kinase, a downstream target of MYD88 s

9 Ibrutinib, an irreversible inhibitor of Bruton's tyrosine kinase, a key enzyme in the signaling

10 pamycin, histone deacetylase, bcl-2, and the Bruton's tyrosine kinase, a pivotal enzyme in the BCR pa

11 88(L265P) triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib.

12 aRIIb1 with BCR inhibits PIP3-dependent Btk (Bruton's tyrosine kinase) activation and the Btk-depende

13 19, as demonstrated by reduced activation of Bruton's tyrosine kinase and extracellular signal-regula

14 significant and dose-dependent inhibition of Bruton's tyrosine kinase and indirectly its downstream s

15 rreversible small-molecule inhibitor of both Bruton's tyrosine kinase and interleukin-2 inducible kin

16 right function is dependent upon both active Bruton's tyrosine kinase and its substrate, the transcri

17 CR-mediated DAG production is dependent upon Bruton's tyrosine kinase and phospholipase C-gamma2, enz

18 Consistent with the essential role for Bruton's tyrosine kinase and phospholipase Cgamma2 in me

19 phorylation of SYK and its immediate targets Bruton's tyrosine kinase and phospholipase Cgamma2.

20 In contrast to the highly successful Bruton's tyrosine kinase and PI3K inhibitors that inhibi

21 ant leukaemic cells expressed high levels of Bruton's tyrosine kinase and two ATP synthetases (ATP5A1

22 e proteins identified by MALDI-TOF including Bruton's tyrosine kinase and X-linked inhibitor of apopt

23 In osteoclasts, loss of CypA activates BtK (Bruton's tyrosine kinase) and subsequently integrates wi

24 n Fyn kinase, independent of Syk, PI3K, Akt, Bruton's tyrosine kinase, and JAK2, and enhanced in the

25 tor tyrosine kinases spleen tyrosine kinase, Bruton's tyrosine kinase, and phosphatidylinositol 3-kin

26 Moreover, B cell linker protein, Bruton's tyrosine kinase, and phospholipase Cgamma2, whi

27 olipase Cgamma2 in mediating PKC activation, Bruton's tyrosine kinase- and phospholipase Cgamma2-defi

28 a possible mechanism of activation unique to Bruton's tyrosine kinase are provided.

29 4-aminocinnoline-3-carboxamide inhibitors of Bruton's tyrosine kinase are reported.

30 s of the anti-apoptotic tyrosine kinase BTK (Bruton's tyrosine kinase) as anti-leukemic agents with a

31 eficient (xid) mice possess mutations in the Bruton's tyrosine kinase (Btk kinase) gene and display d

32 Bruton's tyrosine kinase (Btk) acts downstream of phosph

33 directly to, and stimulates the activity of, Bruton's tyrosine kinase (Btk) and a Ras GTPase-activati

34 d activated the nonreceptor tyrosine kinases Bruton's tyrosine kinase (Btk) and c-Src.

35 is an FDA-approved irreversible inhibitor of Bruton's tyrosine kinase (BTK) and IL-2 inducible T cell

36 have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2-inducible T cell

37 Ibrutinib, an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and IL2-inducible T-cell

38 Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chron

39 B-cell-restricted factor that complexes with Bruton's tyrosine kinase (Btk) and its substrate, transc

40 Two protein-tyrosine kinases, Bruton's tyrosine kinase (Btk) and Syk, and members of t

41 trated that Bright coimmunoprecipitates with Bruton's tyrosine kinase (Btk) and that these proteins a

42 his study, we show that both the stimulatory Bruton's tyrosine kinase (Btk) and the inhibitory SHIP-1

43 Phospholipase Cgamma2 (PLCgamma2) and Bruton's tyrosine kinase (BTK) are constituently associa

44 Defects in Bruton's tyrosine kinase (Btk) are responsible for X chr

45 In the current report, we identified Bruton's tyrosine kinase (BTK) as a functional HIMF bind

46 In this study, we identify Bruton's tyrosine kinase (Btk) as a linker connecting BC

47 Bruton's tyrosine kinase (BTK) belongs to the TEC family

48 Bruton's tyrosine kinase (Btk) binds to phosphatidylinos

49 acologic inhibition and genetic knockdown of Bruton's tyrosine kinase (BTK) blocks AML blast prolifer

50 Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents a

51 Mutations in the gene encoding Bruton's tyrosine kinase (btk) cause the B cell deficien

52 Mutation of Bruton's tyrosine kinase (Btk) causes human X-linked aga

53 Loss of function of Bruton's tyrosine kinase (Btk) causes X-linked agammaglo

54 A fraction of Bruton's tyrosine kinase (Btk) co-localizes with actin f

55 gnaling supports Notch2(+/-)/NOD MZ B cells, Bruton's tyrosine kinase (Btk) deficiency was introduced

56 The MZMO phenotype was reverted in SHIP/Bruton's tyrosine kinase (Btk) double knockout mice, thu

57 tionally, wild type or constitutively active Bruton's tyrosine kinase (Btk) enhanced, whereas the xid

58 Loss of Bruton's tyrosine kinase (Btk) function results in mouse

59 egulating B cell development and activation, Bruton's tyrosine kinase (Btk) functions downstream of m

60 Mutations of the Bruton's tyrosine kinase (btk) gene cause X-linked agamm

61 the pleckstrin homology domain of the mouse Bruton's tyrosine kinase (btk) gene results in an X-link

62 These patients carry mutations in the Bruton's tyrosine kinase (BTK) gene that encode an essen

63 iciency (xid) due to a point mutation in the Bruton's tyrosine kinase (btk) gene.

64 (lo)) expressing 25% of endogenous levels of Bruton's tyrosine kinase (Btk) have B cell functional re

65 Mutation of Bruton's tyrosine kinase (Btk) impairs B cell maturation

66 ncovered a previously unappreciated role for Bruton's tyrosine kinase (Btk) in actin tail formation i

67 We investigated the role of Bruton's tyrosine kinase (Btk) in FcepsilonRI-dependent

68 rs have implicated a role for the Tec kinase Bruton's tyrosine kinase (Btk) in inflammatory cytokine

69 A spontaneous mutation in Bruton's tyrosine kinase (Btk) induces a defect in B-cel

70 olecule inhibitors of BCR signaling kinases, Bruton's tyrosine kinase (Btk) inhibitor ibrutinib and t

71 We show that an analogue of the covalent Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib beari

72 Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has b

73 The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has o

74 a single agent, and in combination with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib or th

75 Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, targets BCR si

76 Mutations in the gene encoding Bruton's tyrosine kinase (BTK) interfere with B cell pro

77 Bruton's tyrosine kinase (BTK) is a critical mediator of

78 Bruton's tyrosine kinase (BTK) is a critical signaling c

79 Bruton's tyrosine kinase (Btk) is a critical signaling m

80 Bruton's tyrosine kinase (Btk) is a critical transducer

81 Bruton's tyrosine kinase (btk) is a cytoplasmic kinase t

82 Bruton's tyrosine kinase (BTK) is a cytoplasmic protein

83 Cytoplasmic Bruton's tyrosine kinase (BTK) is a key component of B c

84 Bruton's tyrosine kinase (BTK) is a mediator of the B-ce

85 Bruton's tyrosine kinase (BTK) is a member of the Src-re

86 Bruton's tyrosine kinase (BTK) is a member of the SRC-re

87 Bruton's tyrosine kinase (BTK) is a member of the Tec no

88 Here we show that Bruton's tyrosine kinase (BTK) is a novel modulator of p

89 Bruton's tyrosine kinase (Btk) is a Tec family non-recep

90 Recent data suggest that Bruton's tyrosine kinase (BTK) is an emerging therapeuti

91 ed that functional, but not kinase-inactive, Bruton's tyrosine kinase (Btk) is critical for Bright ac

92 Bruton's tyrosine kinase (Btk) is essential for B cell a

93 Bruton's tyrosine kinase (Btk) is essential for B-lineag

94 Bruton's tyrosine kinase (Btk) is essential for normal B

95 Bruton's tyrosine kinase (Btk) is essential for normal B

96 Bruton's tyrosine kinase (Btk) is expressed in a variety

97 Bruton's tyrosine kinase (BTK) is important for B cell d

98 Bruton's tyrosine kinase (Btk) is mutated in X-linked ag

99 Bruton's tyrosine kinase (BTK) is pivotal in B cell acti

100 Bruton's tyrosine kinase (Btk) is required for normal B-

101 CD19 and Bruton's tyrosine kinase (Btk) may function along common

102 Bruton's tyrosine kinase (Btk) mediates TLR signaling in

103 Discovery of Bruton's tyrosine kinase (BTK) mutations as the cause fo

104 Bruton's tyrosine kinase (Btk) plays a central role in s

105 Bruton's tyrosine kinase (Btk) plays a critical role in

106 Bruton's tyrosine kinase (Btk) plays a crucial role in B

107 Bruton's tyrosine kinase (Btk) plays pivotal roles in ma

108 Inhibitors of Bruton's tyrosine kinase (BTK) possess much promise for

109 n sequence to 89 kb of mouse sequence in the Bruton's tyrosine kinase (BTK) region.

110 The Tec kinase Bruton's tyrosine kinase (Btk) represents a key intermed

111 Defects in the gene encoding Bruton's tyrosine kinase (Btk) result in a disease calle

112 Defects in Bruton's tyrosine kinase (Btk) result in B cell immunode

113 Defects in the gene for Bruton's tyrosine kinase (Btk) result in the disorder X-

114 Mutations in Bruton's tyrosine kinase (Btk) result in X-linked agamma

115 Loss of function of Bruton's tyrosine kinase (Btk) results in X-linked immun

116 Bruton's tyrosine kinase (BTK) shows constitutive activi

117 in Gqalpha binds directly to the nonreceptor Bruton's tyrosine kinase (Btk) to a region composed of a

118 We demonstrated that the Bruton's tyrosine kinase (Btk) was required for multiple

119 Previously, defects in the gene coding for Bruton's tyrosine kinase (Btk) were shown to result in d

120 uld directly increase the kinase activity of Bruton's tyrosine kinase (Btk) whose defects are respons

121 Therapy targeting Bruton's tyrosine kinase (BTK) with ibrutinib has transf

122 xid mice lack functional Bruton's tyrosine kinase (Btk), a component of the B cel

123 Bruton's tyrosine kinase (Btk), a critical component of

124 Bruton's tyrosine kinase (Btk), a downstream effector of

125 an interact physically and functionally with Bruton's tyrosine kinase (Btk), a hematopoietic non-rece

126 ated cells is mediated by stimulation of the Bruton's tyrosine kinase (BTK), a member of the Src-rela

127 Bruton's tyrosine kinase (Btk), a member of the Tec fami

128 Bruton's tyrosine kinase (BTK), a member of the Tec fami

129 Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine k

130 Bruton's tyrosine kinase (Btk), a Tec-family tyrosine ki

131 Bruton's tyrosine kinase (BTK), an essential component o

132 promoters and requires Bright dimerization, Bruton's tyrosine kinase (Btk), and the Btk substrate, T

133 Ibrutinib, an oral inhibitor of Bruton's tyrosine kinase (BTK), at a once-daily dose of

134 Mice deficient in Bruton's tyrosine kinase (Btk), despite their known defe

135 In cells deficient in Bruton's tyrosine kinase (Btk), Gi-coupled receptors fai

136 an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatmen

137 The ibrutinib target, Bruton's tyrosine kinase (BTK), is essential for B-cell

138 The signaling mediator, Bruton's tyrosine kinase (Btk), is required for certain

139 hree protein tyrosine kinases, Lyn, Syk, and Bruton's tyrosine kinase (Btk), leading to the secretion

140 inhibitors targeting BCR-associated kinases [Bruton's tyrosine kinase (BTK), phosphoinositide 3-kinas

141 been delineated based on the involvements of Bruton's tyrosine kinase (Btk), protein kinase C (PKC),

142 e now report that Bright coprecipitates with Bruton's tyrosine kinase (Btk), the defective enzyme in

143 inical phenotype of patients with defects in Bruton's tyrosine kinase (Btk), the gene that is abnorma

144 Bruton's tyrosine kinase (Btk), the target of inactivati

145 ing ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rit

146 activity of a purified non-receptor kinase, Bruton's tyrosine kinase (Btk), whereas purified alpha-s

147 The PH domain of Bruton's tyrosine kinase (Btk), which is mutated in the

148 peration between the protein tyrosine kinase Bruton's tyrosine kinase (Btk), which regulates the acti

149 Overexpression of human Bruton's tyrosine kinase (Btk), which was activated by H

150 Mast cells derived from Bruton's tyrosine kinase (Btk)-defective xid or btk null

151 posure of wild-type DT40 lymphoma B cells or Bruton's tyrosine kinase (BTK)-deficient DT40 cells reco

152 Bruton's tyrosine kinase (Btk)-deficient human B cells e

153 We show here that Bruton's tyrosine kinase (BTK)-deficient macrophages fai

154 1 (MAV-1) infection of B-cell-deficient and Bruton's tyrosine kinase (Btk)-deficient mice resulted i

155 ther define the nature of the protective Ab, Bruton's tyrosine kinase (Btk)-deficient mice were chara

156 BCR signaling, which is mediated in part by Bruton's tyrosine kinase (BTK).

157 TAT5A can serve as a functional substrate of Bruton's tyrosine kinase (BTK).

158 ly kinases is required for the activation of Bruton's tyrosine kinase (Btk).

159 (XLA) encodes a novel protein kinase termed Bruton's tyrosine kinase (Btk).

160 els of the key downstream signaling molecule Bruton's tyrosine kinase (BTK).

161 Ibrutinib is a potent inhibitor of Bruton's tyrosine kinase (BTK).

162 ults from mutations within the gene encoding Bruton's tyrosine kinase (BTK).

163 vent include C-terminal Src kinase (Csk) and Bruton's tyrosine kinase (Btk).

164 which is caused by mutations in the gene for Bruton's tyrosine kinase (Btk); however, there are femal

165 In contrast, the Bruton's tyrosine kinase (Btk)PH domain specifically bou

166 cute myeloid leukaemia have high activity of Bruton's tyrosine-kinase (BTK) in their blast cells comp

167 ty of kinases (spleen tyrosine kinase [Syk], Bruton's tyrosine kinase [Btk], phosphatidylinositol 3-k

168 In addition, T2 cells from Bruton's tyrosine kinase-deficient Xid mice failed to ge

169 s and inhibited Th2 cytokine production in a Bruton's tyrosine kinase-dependent manner.

170 ndent differences in Lyn phosphorylation and Bruton's tyrosine kinase distribution were observed betw

171 osine kinase R544 on the activation loop and Bruton's tyrosine kinase E445 on the C-helix also aids i

172 PUVA caused poor membrane binding of Akt and Bruton's tyrosine kinase effectors following activation

173 Suppressed expression of c-Src or downstream Bruton's tyrosine kinase, Ets1, Ets2, USF1, or USF2 bloc

174 hich express Bmx and Src as their major Btk (Bruton's tyrosine kinase) family and Src family tyrosine

175 T-cell kinase (Itk) is a member of the Btk (Bruton's tyrosine kinase) family of tyrosine kinases.

176 truct of the pleckstrin homology domain from Bruton's tyrosine kinase (GFP-BTK-PH) localized in intra

177 dentified a novel signaling pathway (c-Src-->Bruton's tyrosine kinase-->transcription factors Ets1, E

178 In B lymphocytes, Bruton's tyrosine kinase has been identified as a TFII-I

179 to homeostatic B cell proliferation require Bruton's tyrosine kinase; however, c-Rel, a Bruton's tyr

180 entify the alpha isoform of the inhibitor of Bruton's tyrosine kinase (IBTKalpha) as a member of the

181 identified the alpha isoform of inhibitor of Bruton's tyrosine kinase (IBTKalpha) as being subject to

182 Mutations in Bruton's tyrosine kinase, immunoglobulin heavy chain and

183 miR-185 is a microRNA (miR) that targets Bruton's tyrosine kinase in B cells, with reductions in

184 phosphatases SHP-1 and SHP-2 but depends on Bruton's tyrosine kinase in DT40 cells.

185 I physically and functionally interacts with Bruton's tyrosine kinase in murine B cells.

186 ngagement bypasses or mitigates the need for Bruton's tyrosine kinase in subsequent BCR signaling for

187 -gamma2 (PLCgamma2), Vav, B cell linker, and Bruton's tyrosine kinase in the formation of highly coor

188 ficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor

189 of ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, in relapsed or refractory pati

190 Bruton's tyrosine kinase; however, c-Rel, a Bruton's tyrosine kinase-induced NF-kappaB/Rel transcrip

191 The activation of N-WASP is suppressed by Bruton's tyrosine kinase-induced WASP activation, and is

192 The Bruton's tyrosine kinase inhibitor ibrutinib effectively

193 The novel Bruton's tyrosine kinase inhibitor ibrutinib has demonst

194 Furthermore, we demonstrate that the Bruton's tyrosine kinase inhibitor ibrutinib or the PI3K

195 synergy, additivity, and antagonism with the Bruton's tyrosine kinase inhibitor ibrutinib, which targ

196 ng, prompting us to combine AZD8835 with the Bruton's tyrosine kinase inhibitor ibrutinib.

197 chronic lymphocytic leukemia (CLL) with the Bruton's tyrosine kinase inhibitor ibrutinib.

198 ortezomib, immunomodulator lenalidomide, and Bruton's tyrosine kinase inhibitor ibrutinib.

199 and in vivo and synergizes strongly with the Bruton's tyrosine kinase inhibitor ibrutinib.

200 ressive clinical responses achieved with the Bruton's tyrosine kinase inhibitor ibrutinib.

201 Ibrutinib is a clinically approved Bruton's tyrosine kinase inhibitor that inhibits mast ce

202 Terreic acid (a Bruton's tyrosine kinase inhibitor) and pergolide (a dop

203 Ibrutinib, a novel oral Bruton's tyrosine kinase inhibitor, has shown single-dru

204 The oral Bruton's tyrosine kinase inhibitor, ibrutinib, has recen

205 ignaling despite treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor.

206 ammalian target of rapamycin inhibitors, and Bruton's tyrosine kinase inhibitors are promising and ma

207 In summary, we show that PI3Kdelta or Bruton's tyrosine kinase inhibitors increase genomic ins

208 Bruton's tyrosine kinase inhibitors remain in the precli

209 (e.g. spleen tyrosine kinase inhibitors and Bruton's tyrosine kinase inhibitors) or the downstream p

210 Bruton's tyrosine kinase is intimately involved in signa

211 en revealed that a BCR signalling component, Bruton's tyrosine kinase, is essential for the survival

212 The human inhibitor of Bruton's tyrosine kinase isoform alpha (IBtkalpha) is a

213 etermined the x-ray crystal structure of the Bruton's tyrosine kinase kinase domain in its unphosphor

214 NMR titration experiments using a Btk (Bruton's tyrosine kinase) kinase domain as a surrogate f

215 inase inhibitors and flavopiridol to inhibit Bruton's tyrosine kinase localization at the membrane an

216 was observed in mutated WM cells exposed to Bruton's tyrosine kinase, mammalian target of rapamycin,

217 The combined use of TMP with Bruton's tyrosine kinase or interleukin-1 receptor-assoc

218 production in a manner that is dependent on Bruton's tyrosine kinase, p38 MAPK, and TANK-binding kin

219 1), as demonstrated by the individual use of Bruton's tyrosine kinase, p38 MAPK, and TBK1 inhibitors.

220 judged by increased levels of phosphorylated Bruton's tyrosine kinase (pBtk), phosphorylated Spleen t

221 We show that the Bruton's tyrosine kinase PH domain binds to PtdIns-3,4,

222 uces an alternate signaling pathway in which Bruton's tyrosine kinase, PI3K, phospholipase Cgamma2, a

223 , and fostamatinib (respective inhibitors of Bruton's tyrosine kinase, PI3Kdelta, and spleen tyrosine

224 conserved electrostatic interaction between Bruton's tyrosine kinase R544 on the activation loop and

225 and phosphorylated tyrosine kinases Lyn and Bruton's tyrosine kinase to membrane rafts after Fc alph

226 Pharmacodynamic data showed Bruton's tyrosine kinase was fully occupied (>90% occupa

227 Activity of Bruton's tyrosine kinase was required for RP105-mediated

228 In a study of Bruton's tyrosine kinase, we find that the use of Previe

229 s are dependent on the BCR signal transducer Bruton's tyrosine kinase, which is dispensable for the T

230 burden in the spleens of B1a cell-deficient Bruton's tyrosine kinase x-linked immunity-deficient (BT